As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo

About this update from Nanoviricides, Inc.

SHELTON, CT / ACCESS Newswire / July 6, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, updates that it has continued to advance its broad-spectrum antiviral drug NV-387 towards a Phase II Clinical Trial of the NV-387 Oral Gummies formulation as a Treatment for the Current Bundibugyo Ebolavirus in the Democratic Republic of Congo (DRC). NanoViricides has already put together a team with a renowned Principal Investigator and with support from a well known University in the Ebola-affected region for the execution of this clinical trial after regulatory approvals. NanoViricides' proposal for the said clinical trial has been approved by the Pillar Committee in Charge in the DRC. The DRC has reported a rapidly expanding number of confirmed cases at 1,561 with 506 confirmed deaths as of July 6, from more than 1,400 cases and 438 deaths reported as of July 2[1]. There is no approved Treatment or Vaccine for the new variant of the Bundibugyo Ebolavirus (BDBV) that is causing the current rapidly expanding outbreak of the Ebolavirus Disease (EVD) in DR Congo and Uganda. The rare Bundibugyo strain of Ebola virus causing the current outbreak appears to be its new variant, likely freshly introduced from some animal source[2], such as fruit bats. NV-387 is the only orally active agent under consideration for clinical trial as a treatment of Ebola to the best of our knowledge. In an epidemic scenario in resource limited settings such as in DRC, oral drug is a highly advantageous feature. Other treatments require infusions. Infusions are difficult to implement and also are not scalable in a large outbreak scenario if this Ebola virus outbreak continues to grow, as has been widely expected. A clinical trial of an antibody cocktail MBP134, alongside MBP134 plus Remdesivir, has started as per WHO with first patient having received infusion of the antibody cocktail on July 2, 2026[3]. Monoclonal antibodies are highly specific to the strain of virus and usually are not effective against unrelated strains. Further, viruses readily escape antibodies after exposure to them. In contrast, NV-387 is a broad-spectrum antiviral that mimics the host-side features that the virus requires, and is likely to be effective against Ebola viruses because they use the same feature mimicked by NV-387...

View stock analysis, news, and events for Nanoviricides, Inc.